ArticleGynecologic oncology reports2020

Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].

Alessandro D Santin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.